Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

XERIS PHARMACEUTICALS, INC.

(XERS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Form 8.3 - The Vanguard Group, Inc. : Xeris Pharmaceuticals, Inc

06/18/2021 | 10:07am EDT
The Vanguard Group, Inc. ( IRSH) 
Form 8.3 - The Vanguard Group, Inc.: Xeris Pharmaceuticals, Inc 
18-Jun-2021 / 15:05 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Ap19 
 
FORM 8.3 
 
IRISH TAKEOVER PANEL 
 
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 
 
DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 
 
1.  KEY INFORMATION 
 
Name of person dealing (Note 1)                                                  The Vanguard Group, Inc. 
Company dealt in                                                                 Xeris Pharmaceuticals, Inc. 
Class of relevant security to which the dealings being disclosed relate (Note 2) USD0.001 Common Stock 
Date of dealing                                                                  16 June 2021 

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

                                             Long            Short 
                                             Numbers   (%)   Numbers (%) 
(1) Relevant securities                      2,670,399 4.02% 
(2) Derivatives (other than options) 
(3) Options and agreements to purchase/sell 
Total                                        2,670,399 4.02% 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:                  Long        Short 
                                             Numbers (%) Numbers (%) 
(1) Relevant securities 
(2) Derivatives (other than options) 
(3) Options and agreements to purchase/sell 
Total 

Ap20

1. Dealings (Note 4)

(a) Purchases and sales

Purchase/sale Number of relevant securities  Price per unit (Note 5) 
Purchase      38,868                         4.16 USD 

(b) Derivatives transactions (other than options transactions)

Product name,  Nature of transaction Number of relevant securities Price per unit 
e.g. CFD       (Note 6)              (Note 7)                      (Note 5) 
Not Applicable 

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, Writing, selling,    Number of securities to               Type, e.g.               Option money paid/ 
              purchasing, varying  which the option relates     Exercise American,         Expiry received per unit 
e.g. call     etc.                 (Note 7)                     price    European etc.     date   (Note 5) 
option 
Not 
Applicable 

(ii) Exercising

Product name,                         Exercise price per unit (Note 5) 
                 Number of securities 
e.g. call option 
Not Applicable 

(e) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction         Price per unit 
                      Details 
(Note 8)                      (if applicable) (Note 5) 
Not Applicable 

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating 
to the voting rights of any relevant securities under any option referred to on this form or relating to the voting 
rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is 
referenced. If none, this should be stated. 
 
 
 
 

Is a Supplemental Form 8 attached? (Note 9) NO

Date of disclosure                                               18 June 2021 
Contact name                                                     Shawn Acker 
Telephone number                                                 001-610-669-8989 
If a connected EFM, name of offeree/offeror with which connected 
If a connected EFM, state nature of connection (Note 10) ----------------------------------------------------------------------------------------------------------------------- 
Category Code: RET - Xeris Pharmaceuticals, Inc 
TIDM:          IRSH 
LEI Code:      5493002789CX3L0CJP65 
Sequence No.:  112340 
EQS News ID:   1209825 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1209825&application_name=news 
 

(END) Dow Jones Newswires

June 18, 2021 10:06 ET (14:06 GMT)

All news about XERIS PHARMACEUTICALS, INC.
08/05XERIS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
08/05XERIS PHARMACEUTICALS : Q2 Earnings Snapshot
AQ
08/05XERIS PHARMACEUTICALS INC : Results of Operations and Financial Condition, Finan..
AQ
08/05XERIS PHARMACEUTICALS : Earnings Flash (XERS) XERIS PHARMACEUTICALS Reports Q2 R..
MT
08/05XERIS PHARMACEUTICALS : Reports Second Quarter 2021 Financial Results and Recent..
BU
07/30XERIS PHARMACEUTICALS : Provides Announcement under the Irish Takeover Rules for..
PU
07/30XERIS PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (for..
AQ
07/29XERIS PHARMACEUTICALS : Provides Announcement Under the Irish Takeover Rules for..
BU
07/29XERIS PHARMACEUTICALS : to Announce Second Quarter 2021 Financial Results and Ho..
BU
07/29XERIS PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial..
AQ
More news
Financials (USD)
Sales 2021 47,5 M - -
Net income 2021 -70,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,25x
Yield 2021 -
Capitalization 165 M 165 M -
Capi. / Sales 2021 3,47x
Capi. / Sales 2022 1,70x
Nbr of Employees 209
Free-Float 98,8%
Chart XERIS PHARMACEUTICALS, INC.
Duration : Period :
Xeris Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends XERIS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 2,48 $
Average target price 8,67 $
Spread / Average Target 249%
EPS Revisions
Managers and Directors
Paul R. Edick Chairman & Chief Executive Officer
John Patrick Shannon President & Chief Operating Officer
Steven Pieper Chief Financial & Accounting Officer
Steven Prestrelski Chief Scientific Officer
Ken Johnson SVP-Clinical Development & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
XERIS PHARMACEUTICALS, INC.-49.59%190
BIONTECH SE396.71%100 096
GILEAD SCIENCES, INC.18.85%86 839
WUXI APPTEC CO., LTD.43.36%72 049
REGENERON PHARMACEUTICALS20.25%60 161
VERTEX PHARMACEUTICALS-14.11%51 779